Vitality Watch

Dossier pubmed preclinical 10-jun-2026
Animal model, organoid, or cell-culture result — not yet human

Systemic characterization of aging-related phenotypes induced by wild-type and G2019S LRRK2 in Caenorhabditis elegans.

Key claim: In C. elegans, wild-type human LRRK2 boosts growth, metabolism, and stress resistance while mildly increasing neuronal vulnerability, whereas the G2019S mutation worsens lifespan, lipid/lipofuscin accumulation, proteostasis, and dopaminergic stress vulnerability.

Abstract

BACKGROUND: Leucine-rich repeat kinase 2 (LRRK2), initially identified as a gene implicated in Parkinson’s disease, is increasingly recognized for its influence on aging and associated disorders. However, its systemic roles in biological aging remain poorly understood. METHODS: To assess its physiological roles, we utilized Caenorhabditis elegans models with pan-neuronal expression of either wild-type or G2019S-mutant human LRRK2. Aging-related phenotypes were evaluated through analyses of development, metabolic activity, oxidative stress response, behavior, neuronal integrity, and proteostasis. Transcriptomic and untargeted metabolomic profiling were conducted to elucidate the molecular consequences of LRRK2 expression and mutation. RESULTS: Wild-type LRRK2 enhanced organismal growth, metabolic activity, and resistance to oxidative and heat stress, while simultaneously inducing mild neurodegenerative alterations. In contrast, the G2019S mutation substantially aggravated aging-associated phenotypes, including reduced lifespan, increased lipid and lipofuscin accumulation, and heightened dopaminergic vulnerability under stress conditions. Multi-omics analyses further showed that wild-type LRRK2 predominantly upregulated pathways related to energy metabolism and specific components of proteostasis, whereas G2019S resulted in diminished amino acid availability, disrupted protein homeostasis, and more pronounced metabolic dysregulation. CONCLUSIONS: Our findings support a bidirectional role of LRRK2 in aging: wild-type LRRK2 promotes systemic metabolic activation and stress resistance but increases neuronal susceptibility, while the G2019S mutation further amplifies metabolic and structural vulnerability. These effects are strongly tissue-dependent and modulated by mutational background. Collectively, this study expands the role of LRRK2 from a Parkinson’s disease-associated protein to a multisystem regulator of aging, providing mechanistic insight and a basis for tissue-selective LRRK2-targeted interventions for age-related disorders.

Why this matters

LRRK2 is primarily pitched as a Parkinson’s target, with inhibitor programs advanced on a dopaminergic-protection narrative. A systemic C. elegans characterization showing that wild-type LRRK2 enhances metabolism and stress resistance while G2019S degrades lipid handling, proteostasis, and lifespan recasts the gene as a mutation-dependent multisystem aging modifier — relevant for anticipating off-target metabolic consequences of pan-LRRK2 inhibition in humans.

Source

Link

Briefing card

Systemic characterization of aging-related phenotypes induced by wild-type and G2019S LRRK2 in Caenorhabditis elegans.
Stage: preclinical · pubmed · 10-jun-2026

If you are following LRRK2-inhibitor drug development for Parkinson's, this worm study suggests wild-type LRRK2 activity also supports metabolism and stress resistance, so systemic inhibition may trade neuronal protection for metabolic cost.

In C. elegans, wild-type human LRRK2 boosts growth, metabolism, and stress resistance while mildly increasing neuronal vulnerability, whereas the G2019S mutation worsens lifespan, lipid/lipofuscin accumulation, proteostasis, and dopaminergic stress vulnerability.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.expneurol.2026.115873

build build 880 · 2bcef25 · 2026-11-18